Your browser doesn't support javascript.
loading
Circulating insulin-like growth factors and risks of overall, aggressive and early-onset prostate cancer: a collaborative analysis of 20 prospective studies and Mendelian randomization analysis.
Watts, Eleanor L; Perez-Cornago, Aurora; Fensom, Georgina K; Smith-Byrne, Karl; Noor, Urwah; Andrews, Colm D; Gunter, Marc J; Holmes, Michael V; Martin, Richard M; Tsilidis, Konstantinos K; Albanes, Demetrius; Barricarte, Aurelio; Bueno-de-Mesquita, H Bas; Cohn, Barbara A; Deschasaux-Tanguy, Melanie; Dimou, Niki L; Ferrucci, Luigi; Flicker, Leon; Freedman, Neal D; Giles, Graham G; Giovannucci, Edward L; Haiman, Christopher A; Hankey, Graham J; Holly, Jeffrey M P; Huang, Jiaqi; Huang, Wen-Yi; Hurwitz, Lauren M; Kaaks, Rudolf; Kubo, Tatsuhiko; Le Marchand, Loic; MacInnis, Robert J; Männistö, Satu; Metter, E Jeffrey; Mikami, Kazuya; Mucci, Lorelei A; Olsen, Anja W; Ozasa, Kotaro; Palli, Domenico; Penney, Kathryn L; Platz, Elizabeth A; Pollak, Michael N; Roobol, Monique J; Schaefer, Catherine A; Schenk, Jeannette M; Stattin, Pär; Tamakoshi, Akiko; Thysell, Elin; Tsai, Chiaojung Jillian; Touvier, Mathilde; Van Den Eeden, Stephen K.
Afiliação
  • Watts EL; Cancer Epidemiology Unit, Nuffield Department of Population Health, University of Oxford, Oxford, UK.
  • Perez-Cornago A; Cancer Epidemiology Unit, Nuffield Department of Population Health, University of Oxford, Oxford, UK.
  • Fensom GK; Cancer Epidemiology Unit, Nuffield Department of Population Health, University of Oxford, Oxford, UK.
  • Smith-Byrne K; Genomic Epidemiology Branch, International Agency for Research on Cancer, Lyon, France.
  • Noor U; Cancer Epidemiology Unit, Nuffield Department of Population Health, University of Oxford, Oxford, UK.
  • Andrews CD; Cancer Epidemiology Unit, Nuffield Department of Population Health, University of Oxford, Oxford, UK.
  • Gunter MJ; Section of Nutrition and Metabolism, International Agency for Research on Cancer, Lyon, France.
  • Holmes MV; Clinical Trial Service Unit and Epidemiological Studies Unit (CTSU), Nuffield Department of Population Health, University of Oxford, Oxford, UK.
  • Martin RM; Medical Research Council Population Health Research Unit, University of Oxford, Oxford, UK.
  • Tsilidis KK; Department of Population Health Sciences, Bristol Medical School, University of Bristol, Bristol, UK.
  • Albanes D; MRC Integrative Epidemiology Unit (IEU), Bristol Medical School, University of Bristol, Bristol, UK.
  • Barricarte A; National Institute for Health Research (NIHR) Bristol Biomedical Research Centre, University Hospitals Bristol NHS Foundation Trust and Weston NHS Foundation Trust and University of Bristol, Bristol, UK.
  • Bueno-de-Mesquita HB; Department of Epidemiology and Biostatistics, School of Public Health, Imperial College London, London, UK.
  • Cohn BA; Department of Hygiene and Epidemiology, University of Ioannina School of Medicine, Ioannina, Greece.
  • Deschasaux-Tanguy M; Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.
  • Dimou NL; Group of Epidemiology of Cancer and Other Chronic Diseases, Navarra Public Health Institute, Pamplona, Spain.
  • Ferrucci L; Group of Epidemiology of Cancer and Other Chronic Diseases, Navarra Institute for Health Research (IdiSNA), Pamplona, Spain.
  • Flicker L; CIBER Epidemiology and Public Health CIBERESP, Madrid, Spain.
  • Freedman ND; Centre for Nutrition, Prevention and Health Services, National Institute for Public Health and the Environment (RIVM), Utrecht, The Netherlands.
  • Giles GG; Child Health and Development Studies, Public Health Institute, Berkeley, CA, USA.
  • Giovannucci EL; Sorbonne Paris Nord University, Nutritional Epidemiology Research Team, Epidemiology and Statistics Research Center, University of Paris, Bobigny, France.
  • Haiman CA; Section of Nutrition and Metabolism, International Agency for Research on Cancer, Lyon, France.
  • Hankey GJ; National Institute on Aging, Baltimore, MD, USA.
  • Holly JMP; WA Centre for Health & Ageing, Medical School, University of Western Australia, Perth, WA, Australia.
  • Huang J; Western Australian Centre for Health and Ageing, University of Western Australia, Perth, WA, Australia.
  • Huang WY; Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.
  • Hurwitz LM; Cancer Epidemiology Division, Cancer Council Victoria, Melbourne, VIC, Australia.
  • Kaaks R; Centre for Epidemiology and Biostatistics, Melbourne School of Population and Global Health, University of Melbourne, Melbourne, VIC, Australia.
  • Kubo T; Precision Medicine, School of Clinical Sciences at Monash Health, Monash University, Melbourne, VIC, Australia.
  • Le Marchand L; Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA, USA.
  • MacInnis RJ; Channing Division of Network Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, USA.
  • Männistö S; Department of Nutrition, Harvard T.H. Chan School of Public Health, Boston, MA, USA.
  • Metter EJ; Department of Preventive Medicine, Center for Genetic Epidemiology, Keck School of Medicine, University of Southern California/Norris Comprehensive Cancer Center, Los Angeles, CA, USA.
  • Mikami K; WA Centre for Health & Ageing, Medical School, University of Western Australia, Perth, WA, Australia.
  • Mucci LA; IGFs & Metabolic Endocrinology Group, Translational Health Sciences, Bristol Medical School, University of Bristol, Bristol, UK.
  • Olsen AW; Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.
  • Ozasa K; National Clinical Research Center for Metabolic Diseases, Key Laboratory of Diabetes Immunology, Ministry of Education, and Department of Metabolism and Endocrinology, Second Xiangya Hospital of Central South University, Changsha, Hunan, China.
  • Palli D; Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.
  • Penney KL; Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.
  • Platz EA; Division of Cancer Epidemiology, German Cancer Research Center (DKFZ), Heidelberg, Germany.
  • Pollak MN; Department of Public Health and Health Policy, Graduate School of Biomedical and Health Sciences, Hiroshima University, Hiroshima, Japan.
  • Roobol MJ; University of Hawaii, Cancer Center, Honolulu, HI, USA.
  • Schaefer CA; Centre for Epidemiology and Biostatistics, Melbourne School of Population and Global Health, University of Melbourne, Melbourne, VIC, Australia.
  • Schenk JM; Precision Medicine, School of Clinical Sciences at Monash Health, Monash University, Melbourne, VIC, Australia.
  • Stattin P; Department of Public Health and Welfare, Finnish Institute for Health and Welfare, Helsinki, Finland.
  • Tamakoshi A; Department of Neurology, College of Medicine, University of Tennessee Health Science Center, Memphis, TN, USA.
  • Thysell E; Departmemt of Urology, Japanese Red Cross Kyoto Daiichi Hospital, Kyoto, Japan.
  • Tsai CJ; Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA, USA.
  • Touvier M; Department of Public Health, Aarhus University, Aarhus, Denmark.
  • Van Den Eeden SK; Danish Cancer Society, Research Center, Copenhagen, Denmark.
Int J Epidemiol ; 52(1): 71-86, 2023 02 08.
Article em En | MEDLINE | ID: mdl-35726641
ABSTRACT

BACKGROUND:

Previous studies had limited power to assess the associations of circulating insulin-like growth factors (IGFs) and IGF-binding proteins (IGFBPs) with clinically relevant prostate cancer as a primary endpoint, and the association of genetically predicted IGF-I with aggressive prostate cancer is not known. We aimed to investigate the associations of IGF-I, IGF-II, IGFBP-1, IGFBP-2 and IGFBP-3 concentrations with overall, aggressive and early-onset prostate cancer.

METHODS:

Prospective analysis of biomarkers using the Endogenous Hormones, Nutritional Biomarkers and Prostate Cancer Collaborative Group dataset (up to 20 studies, 17 009 prostate cancer cases, including 2332 aggressive cases). Odds ratios (OR) and 95% confidence intervals (CI) for prostate cancer were estimated using conditional logistic regression. For IGF-I, two-sample Mendelian randomization (MR) analysis was undertaken using instruments identified using UK Biobank (158 444 men) and outcome data from PRACTICAL (up to 85 554 cases, including 15 167 aggressive cases). Additionally, we used colocalization to rule out confounding by linkage disequilibrium.

RESULTS:

In observational analyses, IGF-I was positively associated with risks of overall (OR per 1 SD = 1.09 95% CI 1.07, 1.11), aggressive (1.09 1.03, 1.16) and possibly early-onset disease (1.11 1.00, 1.24); associations were similar in MR analyses (OR per 1 SD = 1.07 1.00, 1.15; 1.10 1.01, 1.20; and 1.13; 0.98, 1.30, respectively). Colocalization also indicated a shared signal for IGF-I and prostate cancer (PP4 99%). Men with higher IGF-II (1.06 1.02, 1.11) and IGFBP-3 (1.08 1.04, 1.11) had higher risks of overall prostate cancer, whereas higher IGFBP-1 was associated with a lower risk (0.95 0.91, 0.99); these associations were attenuated following adjustment for IGF-I.

CONCLUSIONS:

These findings support the role of IGF-I in the development of prostate cancer, including for aggressive disease.
Assuntos
Palavras-chave
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Neoplasias da Próstata / Fator de Crescimento Insulin-Like I Tipo de estudo: Clinical_trials / Etiology_studies / Observational_studies / Prognostic_studies / Risk_factors_studies Limite: Humans / Male Idioma: En Ano de publicação: 2023 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Neoplasias da Próstata / Fator de Crescimento Insulin-Like I Tipo de estudo: Clinical_trials / Etiology_studies / Observational_studies / Prognostic_studies / Risk_factors_studies Limite: Humans / Male Idioma: En Ano de publicação: 2023 Tipo de documento: Article